Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.
Novel Fluorophore May Reduce Complications in Prostate Cancer Surgery
Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.
Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
BCRFS Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Group
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer
Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
HIFU Yields Noninferior Outcomes Vs Prostatectomy in Local Prostate Cancer
Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.
European Commission Approves Enzalutamide in nmHSPC Subset
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.